Arcturus Q2 revenue $28.3M (-43% YoY); net loss narrows to $9.2M; CF data due Sep

Arcturus Therapeutics Holdings Inc.

2025-Q2 EPS reported -$0.86 revenue$57,683,000

Revenue fell 43% YoY to $28.3M, driven by lower CSL collaboration activity and KOSTAIVE amortization.
Net loss improved to $9.2M ($0.34 loss per share) from $17.2M loss in Q2 2024.
Operating expenses dropped to $39.9M from $71.0M, mainly on lower KOSTAIVE and flu program costs.
Cash and restricted cash $253.4M, extended runway into 2028.
ARCT-032 CF Phase 2 interim data for 9 participants due Sep 2025; KOSTAIVE UK MAA decision expected Sep 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.